Atlas Trials

Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer

Clinical trial NCT05430347 · UNKNOWN

Trial details

NCT number
NCT05430347
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2023-04-15
Primary completion
2025-06-15
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.